Abattis Bioceuticals (ATTBF) Stock Statistics & Valuation Metrics

Abattis Bioceuticals has a market cap or net worth of $478.00. The enterprise value is $10.83M.

Abattis Bioceuticals has 477,804,140 shares outstanding. The number of shares has decreased by -2.65% in one year.

Abattis Bioceuticals’s return on equity (ROE) is -0.27 and return on invested capital (ROIC) is -25.78%.

The current PE Ratio of Abattis Bioceuticals is -3.71. Abattis Bioceuticals’s PEG ratio is 0.04.

In the last 12 months, Abattis Bioceuticals had revenue of 356.88K and earned -3.04M in profits. Earnings per share was -0.01.

In the last 12 months, operating cash flow was 9.41M and capital expenditures -5.06M, giving a free cash flow of 4.35M billion.

Abattis Bioceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Abattis Bioceuticals upcoming earnings date is ―, ―.

Abattis Bioceuticals as a current ratio of 0.73, with Debt / Equity ratio of 14.17%

In the past 12 months, Abattis Bioceuticals has paid 88.53K in taxes.

Abattis Bioceuticals EV to EBITDA ratio is -2.81, with an EV/FCF ratio of 2.49.

Abattis Bioceuticals has $2.40M in cash and marketable securities with C$1.57M in debt, giving a net cash position of -$832.69K billion.

Gross margin is 67.62%, with operating margin of -1108.73%, and net profit margin of -852.40%.

The average price target for Abattis Bioceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―